TickerGuard
Buy Day today: Neutral (47) Mixed market breadth · no major macro event
IONS

Ionis Pharmaceuticals Inc

Healthcare · Biotechnology

44.20$ +0.4% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

Ionis Pharmaceuticals Inc (IONS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 2,995 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet IONS
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
844 912 1,084 1,091 1,253 1,322 1,300 2,247 2,248 2,668 2,836 2,878 2,895 3,233 3,091 3,079 3,096 2,390 2,249 2,497 2,415 2,612 2,519 2,456 2,422 2,534 2,885 2,971 2,934 2,764 2,764 2,691 3,081 3,004 2,813 2,985 3,033 3,524 3,450 2,995
730 798 962 964 1,111 1,168 1,143 2,083 2,079 2,208 2,374 2,415 2,408 2,721 2,558 2,531 2,537 2,130 1,989 2,238 2,156 2,345 2,253 2,191 2,152 2,203 2,543 2,617 2,585 2,416 2,416 2,329 2,714 2,620 2,419 2,577 2,519 2,990 2,937 2,491
84 665 114 856 159 1,023 1,035 805 480 2,084 376 2,262 248 2,500 486 530 633 1,892 414 565 633 2,115 543 522 315 276 309 425 352 349 349 294 335 242 264 297 338 372 173 350
697 668 860 856 1,011 1,023 1,035 1,980 1,959 2,084 2,254 2,262 2,221 2,500 2,384 2,349 2,329 1,892 1,820 2,059 1,987 2,115 2,052 2,022 1,982 1,987 2,347 2,385 2,236 2,206 2,206 2,079 2,483 2,298 2,145 2,290 2,240 2,677 1,919 2,055
8.5 108 69 51 43 63 37 17 15 13 10 32 49 63 29 28 39 76 23 24 9.1 62 26 6.8 6.6 26 14 28 142 5.1 5.1 27 18 92 40 53 25 66 74 59
9.3 7.5 6.8 6.5 8.5 10.0 9.1 9.1 8.4 8.6 11 19 19 18 23 24 22 22 22 24 23 25 24 20 21 22 22 26 26 30 30 29 28 13 12 8.5 10 10 5.6 51
91 93 95 100 117 122 123 128 132 132 134 135 149 154 164 173 182 181 180 179 180 178 178 177 181 74 85 92 – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
21 20 21 21 22 22 23 23 24 24 25 26 27 26 27 28 28 28 29 29 30 29 29 29 30 – – – – – – – – – – – – – – –
704 813 882 875 855 903 912 1,430 1,408 1,481 1,448 1,421 1,397 1,548 1,521 1,484 1,489 1,547 1,568 1,914 1,884 1,840 1,810 1,831 1,828 1,961 2,399 2,543 2,619 2,467 2,467 2,427 2,419 2,415 2,337 2,353 2,415 3,035 2,959 2,555
107 134 171 192 178 225 213 249 260 280 252 241 232 273 258 231 245 290 295 294 280 241 228 268 283 312 259 288 404 328 328 306 305 309 250 897 903 782 717 316
0.0 1.2 0.1 21 0.1 1.6 0.0 1.2 14 14 15 14 2.1 2.0 4.2 5.0 5.8 293 62 62 62 3.5 4,206 4,732 5.0 7.5 11 25 10.0 44 44 44 44 9.3 12 630 631 453 433 242
16 21 23 13 24 25 14 13 14 29 13 16 13 16 21 7.4 16 17 9.5 15 8.4 12 16 10 21 18 10 24 5.6 13 13 9.2 9.1 43 17 23 14 28 26 48
408 501 508 517 584 593 601 610 619 628 637 647 656 770 780 789 799 516 848 1,241 1,220 1,221 1,222 1,223 1,224 1,183 1,184 1,299 1,231 1,230 1,231 1,232 1,234 1,245 1,251 625 596 1,347 1,349 1,351
140 100 202 216 308 331 301 696 711 1,048 1,208 1,269 1,336 1,471 1,360 1,377 1,383 843 681 583 531 772 710 625 594 573 487 428 315 297 297 264 662 588 476 632 618 489 491 440
-1,207 -1,181 -1,178 -1,189 -1,190 -1,187 -1,242 -1,283 -1,287 -967 -883 -884 -858 -708 -846 -878 -909 -1,249 -1,221 -1,302 -1,385 -1,160 -1,225 -1,330 -1,377 -1,430 -1,554 -1,639 -1,787 -1,939 -1,939 -2,005 -2,145 -2,250 -2,397 -2,273 -2,402 -2,631 -2,724 -2,838
123 124 125 124 124 127 125 129 137 150 142 140 143 153 139 139 140 140 141 141 141 160 142 142 142 142 143 143 143 146 146 146 149 158 159 182 161 162 165 165

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?